The Latest Breaking News from Jaguar Health

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…

Benzinga · Aug 30, 2022

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE:MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD). Merck shares traded in a range of $89.72 to $90.97 on day volume of 5.2…

Benzinga · Aug 23, 2022

Jaguar Health's Return On Capital Employed Insights

Jaguar Health (NASDAQ:JAGX) brought in sales totaling $2.62 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 26.86%, resulting in a loss of $18.16 million.

Benzinga · Jun 3, 2022